Lupin, Cipla and Aurobindo: Axis Securities advises to buy these 3 pharma firms after Q1 earnings – key reasons
Source: mintgenie.livemint.com In the June quarter (Q1FY24), the pharma space posted robust revenue growth on account of volume ramp-up, new launches (especially Revlimid), and stabilising pricing pressure in the US base business, said brokerage house Axis Securities in a review note. The brokerage’s pharma coverage universe posted a 20.5 percent YoY rise in revenue for […]